If not for the coronavirus and a highly contested U.S. presidential election, 2020 might just be the year of the biopharma financing. With 1,320 transactions tallied and the amount raised hitting $115.77 billion, the year represents the highest volume and value for the industry to date.
When entrepreneurs and emerging businesses raise seed capital for a new business or generate funding for business growth, they often turn to the exempt offering framework under the Securities Act. However, when doing so, they are faced with a confusing and complex system that must be navigated. To simplify the process, the SEC has announced that it is amending its rules that govern offering exemptions, which small and medium-sized business rely on to raise capital.
The dramatic increase in COVID-19 infections in Europe and the U.S., combined with information overload surrounding the lead up to the Nov. 3 contentious U.S. presidential election, was more than enough to send investors to the sidelines in October.
October brought another burgeoning swell of pandemic news with the U.S. granting its first FDA approval for a COVID-19 therapy, a promising vaccine candidate reaching full enrollment in phase III, and the stoppage of several trials due to safety signals.
Two complete response letters for group members dispatched this month by the FDA was enough to contribute to a flat performance in October for the BioWorld Neurological Diseases index. Overall, the price-weighted index has remained underwater for most of the year with its value down about 5% during this period.
RSS
